PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Vedolizumab is an anti-inflammatory monoclonal antibody that exclusively targets the α4β7 integrin. We aimed to systematically review the efficacy and safety of vedolizumab for patients with inflammatory bowel diseases (IBDs). PubMed, EMBASE, and the Cochrane Library were searched up to May 2014. Ra...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Medicine (Baltimore)
Hlavní autoři: Wang, Man Cai, Zhang, Ling Yi, Han, Wei, Shao, Yuan, Chen, Mo, Ni, Rui, Wang, Gen Nian, Wei, Feng Xian, Zhang, Ya Wu, Xu, Xiao Dong, Zhang, You Cheng
Médium: Artigo
Jazyk:Inglês
Vydáno: Wolters Kluwer Health 2014
Témata:
4200
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4603082/
https://ncbi.nlm.nih.gov/pubmed/25526490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000000326
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky